According to Zhitong Finance and Economics, GE HealthCare (GEHC.US) has agreed to acquire the remaining 50% of shares of Nihon Medi-Physics (NMP) from Sumitomo Chemical, aiming to obtain full ownership of this Japanese radiopharmaceutical company. The company expects the transaction to be completed in early 2025. The transaction is expected to have a neutral impact on GE Healthcare's adjusted earnings per share in the first year, followed by an increase in earnings.

With this development, GE HealthCare plans to strengthen its expertise in radiopharmaceuticals for various disease detection and diagnostic imaging procedures. NMP's product portfolio includes GE HealthCare's radiopharmaceuticals used in clinical imaging for neurology, cardiology, and oncology surgeries. NMP generated around $0.183 billion in revenue in 2023. It has 13 manufacturing facilities and is also focused on research and development, including non-clinical and clinical development of radiotracers as well as theranostics research.

This move will strengthen GE HealthCare's pharmaceutical diagnostics division and increase opportunities for patients in Japan and Asia to access next-generation radiopharmaceuticals. Since the acquisition of Amersham plc in 2004, GE HealthCare has held a 50% stake in NMP and has held three positions on its board of directors.